(281) Low-Intensity Shockwave Therapy Combined with Tadalafil 5mg Daily has Better Efficacy for Mild and Moderate Erectile Dysfunction: The Preliminary Results of a Multicenter Clinical Study in China

M Lu,Y Huang,Y Chen,S Yuan

DOI: https://doi.org/10.1093/jsxmed/qdae002.243

2024-03-06

The Journal of Sexual Medicine

Abstract:Introduction Most clinical studies have demonstrated that low-intensity extracorporeal shockwave therapy (Li-ESWT) can improved erectile function in patients with erectile dysfunction (ED). The EAU guideline recommended to use Li-ESWT for mild vasculogenic ED patients. However, the therapeutic advantages of Li-ESWT combined with phosphodiesterase type 5 inhibitors (PDE5i) have not been explored clearly in clinical practice for mild and moderate ED patients. Objective To compare the therapeutic effects of Li-ESWT and Li-ESWT combined with PDE5i in mild and moderate ED patients with 8≤IIEF-5≤16 from a multicenter clinical study in China. Methods Patients with ED which IIEF-5 score is less than 22 and aged 18–60 years old were enrolled from three clinical centers from Jun. 2019 to Mar. 2023. The demographic data, International Index of Erectile Function-5 (IIEF-5), erectile hardness score (EHS) and self-reported symptom questions were collected. Patients were treated by a linear low-energy shock waves generator (Renova). Low-intensity shock wave (energy density of 0.09mJ/mm2) treatments were applied (once a week, 4 weeks in total, 5000 shocks each time). Patients in Li-ESWT combined with PDE5i group took 5mg of tadalafil once a day for one continuous month during ESWT. Comparative analyses of pre- and post-treatment and intergroup were used for statistics. Results In total, 42 ED cases (37.43±11.86 years) in Li-ESWT group and 116 cases (37.41±10.14 years) in combined group were enrolled for analysis. The IIEF-5 score and EHS in both groups were significantly improved after 1 month treatment (p<0.01). Compared with Li-ESWT group, patients in combined group significantly had higher self-reported efficiency (61.2% vs. 47.6%, p=0.013), IIEF-5 scores (15.34±7.15 vs. 13.96±7.71, p=0.039) and EHS (2.85±0.82 vs. 2.69±0.89, p=0.050). In the mild and moderate ED (with 8≤IIEF-5≤16) sub-group, 30 ED cases (36.81±10.99 years) in Li-ESWT group and 96 cases (36.80±10.69 years) in combined group were enrolled for analysis. The combined regimen showed better therapeutic advantages, including effective parameters IIEF-5(14.50±6.74 vs. 12.87±8.54, p=0.040), EHS (2.85±0.75 vs. 2.81±0.67, p=0.046) and self-reported efficiency (64.2% vs. 54.1%, p=0.001). Conclusions Li-ESWT can effectively improve erectile function in this multicenter clinical study in China, and the combination of Li-ESWT with daily use PDE5i had a better therapeutic effect on Chinese ED patients, especially on mild and moderate ED. Long-term follow-up with large sample study need to be developed for exploring the optimal therapeutic regimen. Disclosure No.

urology & nephrology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the efficacy of low - intensity extracorporeal shock wave therapy (Li - ESWT) in combination with daily use of phosphodiesterase type 5 inhibitors (PDE5i, such as tadalafil 5mg) in the treatment of patients with mild - to - moderate erectile dysfunction (ED), and compare it with Li - ESWT alone.

Specifically, the researchers hope to verify the following points:
1. **Efficacy of Li - ESWT**: Whether Li - ESWT alone can effectively improve the erectile function of patients with mild - to - moderate ED.
2. **Efficacy of combined treatment**: Whether the combined use of Li - ESWT and PDE5i has a better treatment effect than Li - ESWT alone.
3. **Specific indicators of treatment effect**: Evaluate the treatment effect through the International Index of Erectile Function - 5 (IIEF - 5), Erectile Hardness Score (EHS) and patient - self - reported symptom questionnaires.

The research background points out that most clinical studies have shown that Li - ESWT can improve the erectile function of ED patients, and the European Association of Urology (EAU) guidelines recommend its use for patients with mild vascular ED. However, the treatment advantages of the combined use of Li - ESWT and PDE5i are not yet clear clinically, especially in the application for patients with mild - to - moderate ED.

Therefore, this study aims to systematically evaluate the effects of these two treatment methods through a multi - center clinical trial, in order to provide more effective treatment options for clinical practice.